본문으로 건너뛰기
← 뒤로

Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020-2025).

1/5 보강
International immunopharmacology 📖 저널 OA 6.5% 2022: 0/3 OA 2023: 1/2 OA 2024: 1/21 OA 2025: 0/97 OA 2026: 15/138 OA 2022~2026 2026 Vol.172() p. 116249
Retraction 확인
출처

Liu R, Qi J, Liu Y, Hou M, Zhang M, An X, Hu J

📝 환자 설명용 한 줄

Abnormalities in protein tyrosine kinases (PTKs) are one of the primary drivers of cancer.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Liu R, Qi J, et al. (2026). Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020-2025).. International immunopharmacology, 172, 116249. https://doi.org/10.1016/j.intimp.2026.116249
MLA Liu R, et al.. "Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020-2025).." International immunopharmacology, vol. 172, 2026, pp. 116249.
PMID 41576567 ↗

Abstract

Abnormalities in protein tyrosine kinases (PTKs) are one of the primary drivers of cancer. As a receptor subfamily, fibroblast growth factor receptors (FGFRs) comprise four subtypes-FGFR1 to FGFR4. Their abnormal intracellular expression is a significant cause of tumorigenesis, making FGFRs key therapeutic targets in cancer treatment. This paper primarily summarizes the latest research advances in FGFR inhibitors, aiming to provide insights for future design and synthesis studies of FGFR inhibitors.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반